Thursday, September 18, 2025 9/18/2025

BMT Core- The Ohio State University blood and marrow transplant research consortium

Award Number: UG1HL109322
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/08/2011
PERIOD OF PERFORMANCE END DATE: 06/30/2031

Group Awards By:

View Award Description

BMT Core- The Ohio State University blood and marrow transplant research consortium - PROJECT SUMMARY Chimeric antigen receptor T cells, or CAR T, are engineered white blood cells from patients that can destroy cancer. CAR T has the potential to cure several blood cancers, including leukemia and lymphoma. However, side effects of CAR T, called cytokine release syndrome (CRS) and neurotoxicity, can cause life-threatening problems with patients’ blood pressure, breathing, and brain. We developed a system to identify patients at risk of severe CRS and neurotoxicity by measuring two simple blood tests, CRP and ferritin, well before the CAR T are even given. We now propose a new approach to prevent CRS and neurotoxicity among those patients at greatest risk of CRS and neurotoxicity. This entails treating these high-risk patients with two prophylactic medications, dexamethasone and anakinra, before they show any signs of CAR T toxicity. In smaller studies, prophylactic dexamethasone or anakinra have been shown to be safe and offer strong signals of success in preventing CRS or neurotoxicity after CAR T. They have not yet been studied as a combination in this setting. Our proposed trial will be a large study of 182 patients who receive either dexamethasone plus anakinra or a placebo within the first few days of receiving CAR T. We will closely monitor patients for signs of CRS and/or neurotoxicity within the first 30 days of CAR T therapy, when this risk is the greatest. It is important to highlight that Hispanic patients are at 3 times greater risk for severe CRS, compared to White non-Hispanic patients. We will specifically investigate whether preventative dexamethasone and anakinra reduces the risk of such severe toxicity among Hispanic patients, and improve CAR T health equity. Work in the lab also suggests that preventing CRS and neurotoxicity will not only help to make CAR T therapy safer, but possibly more effective against cancer too. Research from our group shows that preventing CRS and neurotoxicity prevents the patient’s immune system from impairing CAR T function via a metabolite called arginine. We expect that successful completion of this project will facilitate safe CAR T therapy and possibly improve curative outcomes for treated cancer patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $233,355 )
2025	2025	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	003	15	8/6/2025	NON-COMPETING CONTINUATION	$233,355
2025	2024	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	002	14	2/17/2025	COMPETING CONTINUATION	$311,023
2025	2023	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	001	13	2/17/2025	NON-COMPETING CONTINUATION	-$173,511
2025	2022	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	000	12	2/17/2025	NON-COMPETING CONTINUATION	-$137,512
														Subtotal = $233,355

Issue Date FY: 2024 ( Subtotal = $262,868 )
2024	2024	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	001	14	8/15/2024	COMPETING CONTINUATION	$262,868
2024	2023	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	000	13	8/9/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $262,868

Issue Date FY: 2023 ( Subtotal = $173,511 )
2023	2023	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	000	13	6/29/2023	NON-COMPETING CONTINUATION	$173,511
														Subtotal = $173,511

Issue Date FY: 2022 ( Subtotal = $175,490 )
2022	2022	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	000	12	7/1/2022	NON-COMPETING CONTINUATION	$175,490
														Subtotal = $175,490

Issue Date FY: 2021 ( Subtotal = $177,249 )
2021	2021	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	000	11	6/15/2021	NON-COMPETING CONTINUATION	$177,249
														Subtotal = $177,249

Issue Date FY: 2020 ( Subtotal = $179,429 )
2020	2020	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	000	10	6/9/2020	NON-COMPETING CONTINUATION	$179,429
														Subtotal = $179,429

Issue Date FY: 2019 ( Subtotal = $268,839 )
2019	2019	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	001	9	6/13/2019	NON-COMPETING CONTINUATION	$181,553
2019	2017	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	000	7	10/25/2018	COMPETING CONTINUATION	$87,286
														Subtotal = $268,839

Issue Date FY: 2018 ( Subtotal = $189,704 )
2018	2018	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	000	8	7/18/2018	NON-COMPETING CONTINUATION	$189,704
														Subtotal = $189,704

Issue Date FY: 2017 ( Subtotal = $194,009 )
2017	2017	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	000	7	7/26/2017	COMPETING CONTINUATION	$194,009
2017	2017	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Blood Diseases and Resources Research	001	7	8/22/2017	COMPETING CONTINUATION	$0
														Subtotal = $194,009

Grand Total All Awards = $1,854,454

Top

All Categories

About

Search

Reports

Data Submission

Award Information

BMT Core- The Ohio State University blood and marrow transplant research consortium

Award Number: UG1HL109322

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/08/2011

PERIOD OF PERFORMANCE END DATE: 06/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer